Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I first-in-human, dose escalation trial of MCARH109 in patients with relapsed or refractory multiple myeloma

Next Previous
X
Search
Trial Profile

Phase I first-in-human, dose escalation trial of MCARH109 in patients with relapsed or refractory multiple myeloma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MCARH 109 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors Eureka Therapeutics

    • Most Recent Events

    • 29 Sep 2022 Results published in the New England Journal of Medicine
    • 28 Sep 2022 According to an Eureka Therapeutics Media Release, results published in the New England Journal of Medicine.
    • 28 Sep 2022 Results published in Eureka Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top